This Human IFN-Beta ELISA measures interferon beta levels in human serum, plasma, and tissue culture samples with 1.2 pg/ml LLOQ sensitivity. This kit has been validated for the measurement of IFN-Beta in autoimmune serum and of trademarked IFN-Beta 1a and IFN-Beta 1b therapeutic molecules in human serum. There is no detection inhibition by 3-log excess of soluble IFNAR2 protein.
Product Name: VeriKine-HS Human Interferon-Beta ELISA Kit (Serum, Plasma, TCM)
Levels of IFN-Beta Quantified in Normal Human Sera (NHS) and Multiple Sclerosis (MS) Patient Sera
Representative Human IFN-Beta Standard Curve from 1.2-150 pg/ml using Protocol A.
Representative Human IFN-Beta Standard Curve from 2.3-150 pg/ml using Protocol B.
Correlation between IFN-Beta Standards prepared in Standard Diluent & Healthy Serum Pools.
Standard Diluent mimics Healthy Donor Serum (HDS) in quantifying spiked IFN-Beta 1a.
| Matrix Compatibility | Serum, Plasma, Tissue Culture Media (TCM) |
|---|---|
| Assay Range | Protocol A: 1.2 - 150 pg/ml (for improved serum performance) Protocol B: 2.3 - 150 pg/ml |
| LLOQ | 1.2 pg/ml Need more sensitivity? Check out our Sample Testing Services |
| Assay Length | Protocol A: 3 hours, 30 minutes Protocol B: 3 hours |
| Specificity | Human IFN-β |
The VeriKine-HS Human IFN-Beta ELISA Kit is designed to measure low or basal levels of Human IFN-Beta in autoimmune disease sera, healthy serum/plasma, or tissue culture media samples with 1.2 pg/ml LLOQ sensitivity.
This assay is suitable for the measurement of trademarked therapeutic molecules in human serum samples. Researchers and clinical investigators examining a) the pharmacokinetics of IFN-Beta molecules, b) IFN-Beta as a biomarker, or c) IFN-Beta as a pharmacodynamic marker of TLR agent or other immune response modifier activity will find this immunoassay to be an essential laboratory tool.
*For a TCM-compatible ELISA, we recommend our Human IFN-Beta ELISA Kit, High Sensitivity (Cat. No. 41435-1).
Technical Data Sheet, Certificate of Analysis (CoA), Protocol, and Safety Data Sheet (SDS)
41415 Certificate of Analysis and Protocol A
41415 Certificate of Analysis and Protocol B
41415 Technical Data Sheet
Performance Characterization of a High Sensitivity Human Interferon Beta ELISA Kit in Healthy Serum, Patient Serum and Plasma Samples
| CVs and Spike Recovery | Inter-Assay < 8%
Spike Recovery > 90% in Serum |
|---|---|
Cross-reactivity
| No cross-reactivity detected with:
|
| Synonyms | Human Beta Interferon, Human Fibroblast IFN, Human IFN Beta, Human Fibroblast Interferon, Human Beta IFN, Human Type I Interferon Beta, Human IFN B |
| Storage | 2-8°C |
| Expiration Date | 12 months from the date of manufacture |
| Shipping Condition | Wet Ice |
Interferon beta (IFN-Beta, IFNb) is part of the first wave of cytokine response in cells. Pathogen infection can result in the activation of interferon regulatory factor 3 (IRF3) which functions in trans to activate IFN-Beta gene transcription. IFN-Beta is biologically unique when compared to other interferons and studies have shown that IFN-Beta has overlapping and distinct gene expression patterns as compared to IFN-Alpha. It appears that IFN-Beta binds to the Type I IFN receptor with higher affinity than the other Type I IFNs and it may also regulate receptor internalization in a different manner. Additionally, IFN-Beta has long been known to inhibit viral replication as part of the body’s innate antiviral response and is used as a therapeutic for the treatment of Multiple Sclerosis (MS) and some tumors.
Powered by Bioz